Baidu
map

NEJM:冰岛对SARS-CoV-2体液免疫应答的研究成果可喜

2020-09-02 MedSci原创 MedSci原创

研究结果表明,抗SARS-CoV-2的抗病毒抗体在确诊后4个月内没有下降。

目前,研究者对SARS-CoV-2感染后体液免疫反应的性质和持久性知之甚少。大多数COVID-19患者的血清转化发生在诊断714天,西班牙一项对61000人的研究表明,5%的人口已经形成了针对棘突蛋白和核蛋白的抗体,三分之一的感染者没有症状。这表明,相当一部分感染者在恢复早期抗体呈阴性。有几项研究报告称,重症患者SARS-CoV-2抗体水平高于无症状或轻度症状的患者。

对于无症状感染或轻度症状患者,迫切需要一种高效的血清学检测。即血清筛查亲和力低的人群(如冰岛的人群)需要一种高度特异性的试验。

本研究的目的是评估冰岛人群中SARSCoV-2的血清亲和力,并评估SARS-CoV-2感染后4个月内抗体水平的纵向变化,以及这种变化与性别、年龄、现有表型和Covid-19症状的相关性。我们在两组qPCR阳性人群和六组未进行qPCR检测或已进行qPCR检测且阴性结果的人群中,采用六种不同的检测方法筛选了SARSCov-2阳性血清抗体。

本研究中使用的八个样本组的简图概述。Humoral Immune Response to SARS-CoV-2 in Iceland. DOI: 10.1056/NEJMoa2026116

研究结果显示,在1797名从SARS-CoV-2感染中康复的患者中,1215名接受检测的患者中有1107人(91.1%)血清阳性;在qPCR诊断后的2个月内,两种pan-Ig检测的抗病毒抗体滴度升高,并在余下的研究中保持平稳。SARS-CoV-2的抗病毒抗体在确诊后的4个月内没有下降。在被隔离者中,2.3%的人血清阳性;在那些未知暴露的人中,有0.3%是阳性的。研究者估计0.9%的冰岛人感染了SARS-CoV-2病毒,感染后死亡的只有0.3%。研究者也估计56%的冰岛SARS-CoV-2感染被诊断出患有qPCR, 14%发生在隔离的人没有进行qPCR检查(或者检测结果为阴性)。

qPCR阳性病例中,抗体流行率和滴度与qPCR诊断后的时间有关。Humoral Immune Response to SARS-CoV-2 in Iceland. DOI: 10.1056/NEJMoa2026116

qPCR诊断患者重复Pan-Ig抗体检测结果* (两个样品至少间隔30天获得。对于每个样本,一个人可能在两种测试中都是阳性,或者在单一测试中是阳性,或者在两种测试中都是阳性。显示的是每个结果的人数和占总数的百分比(N=487)。)

在康复者中,老年人和SARS-CoV-2感染较严重者的抗体水平较高。在两次spike蛋白抗体检测中,女性的抗体水平较男性低,她们患病的几率较低。吸烟者的SARS-CoV-2抗体水平较低。吸烟会增加年轻成年人罹患严重Covid-19疾病的可能性,有报道称吸烟会增加ACE2的表达,ACE2SARS-CoV-2病毒进入细胞的受体。就临床特征而言,抗体水平与住院和临床严重程度最密切相关,其次是临床症状,如发烧、最高体温读数、咳嗽和食欲不振。除能量损失外,这些个体症状的严重程度与较高的抗体水平有关。

总而言之,基因解码公司首席执行官、研究论文高级作者卡里-斯特凡松(Kari Stefansson)表示:“我们很高兴能够消除以下顾虑,即在感染几周之后,抗病毒抗体滴度有可能会下降。我们现在主要是关注研究那些没有提升抗体水平的人的细胞介导免疫。”

参考文献:Daniel F. Gudbjartsson, Gudmundur L. Norddahl. et al. Humoral Immune Response to SARS-CoV-2 in Iceland.  NEJM. September 1, 2020. DOI: 10.1056/NEJMoa2026116

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1004072, encodeId=6ac510040e299, content=<a href='/topic/show?id=0e2531050aa' target=_blank style='color:#2F92EE;'>#冰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31050, encryptionId=0e2531050aa, topicName=冰岛)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=小小医者, createdTime=Fri Jul 30 22:13:56 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937952, encodeId=ba3d193e9523e, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun Apr 11 21:36:06 CST 2021, time=2021-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898539, encodeId=d9c21898539cb, content=<a href='/topic/show?id=0bdfe3394a4' target=_blank style='color:#2F92EE;'>#研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73394, encryptionId=0bdfe3394a4, topicName=研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Tue Feb 02 07:36:06 CST 2021, time=2021-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321218, encodeId=8bfc1321218af, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Fri Sep 04 04:36:06 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400250, encodeId=a4c0140025052, content=<a href='/topic/show?id=10cc2901458' target=_blank style='color:#2F92EE;'>#免疫应答#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29014, encryptionId=10cc2901458, topicName=免疫应答)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a602256775, createdName=clmlylxy, createdTime=Fri Sep 04 04:36:06 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035398, encodeId=e2ca103539882, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Sep 02 16:36:06 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882186, encodeId=8209882186b5, content=<a href='/topic/show?id=8f4310385673' target=_blank style='color:#2F92EE;'>#COVID-19血清学抗体#</a> 抗体检测对二次感染风险的评估很重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103856, encryptionId=8f4310385673, topicName=COVID-19血清学抗体)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211106/ea1e44326e0946358e849b176cb8f385/463bdae7ebb241129b21a5680b639742.jpg, createdBy=329c5121051, createdName=liangying, createdTime=Wed Sep 02 13:52:06 CST 2020, time=2020-09-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1004072, encodeId=6ac510040e299, content=<a href='/topic/show?id=0e2531050aa' target=_blank style='color:#2F92EE;'>#冰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31050, encryptionId=0e2531050aa, topicName=冰岛)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=小小医者, createdTime=Fri Jul 30 22:13:56 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937952, encodeId=ba3d193e9523e, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun Apr 11 21:36:06 CST 2021, time=2021-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898539, encodeId=d9c21898539cb, content=<a href='/topic/show?id=0bdfe3394a4' target=_blank style='color:#2F92EE;'>#研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73394, encryptionId=0bdfe3394a4, topicName=研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Tue Feb 02 07:36:06 CST 2021, time=2021-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321218, encodeId=8bfc1321218af, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Fri Sep 04 04:36:06 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400250, encodeId=a4c0140025052, content=<a href='/topic/show?id=10cc2901458' target=_blank style='color:#2F92EE;'>#免疫应答#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29014, encryptionId=10cc2901458, topicName=免疫应答)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a602256775, createdName=clmlylxy, createdTime=Fri Sep 04 04:36:06 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035398, encodeId=e2ca103539882, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Sep 02 16:36:06 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882186, encodeId=8209882186b5, content=<a href='/topic/show?id=8f4310385673' target=_blank style='color:#2F92EE;'>#COVID-19血清学抗体#</a> 抗体检测对二次感染风险的评估很重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103856, encryptionId=8f4310385673, topicName=COVID-19血清学抗体)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211106/ea1e44326e0946358e849b176cb8f385/463bdae7ebb241129b21a5680b639742.jpg, createdBy=329c5121051, createdName=liangying, createdTime=Wed Sep 02 13:52:06 CST 2020, time=2020-09-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1004072, encodeId=6ac510040e299, content=<a href='/topic/show?id=0e2531050aa' target=_blank style='color:#2F92EE;'>#冰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31050, encryptionId=0e2531050aa, topicName=冰岛)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=小小医者, createdTime=Fri Jul 30 22:13:56 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937952, encodeId=ba3d193e9523e, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun Apr 11 21:36:06 CST 2021, time=2021-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898539, encodeId=d9c21898539cb, content=<a href='/topic/show?id=0bdfe3394a4' target=_blank style='color:#2F92EE;'>#研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73394, encryptionId=0bdfe3394a4, topicName=研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Tue Feb 02 07:36:06 CST 2021, time=2021-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321218, encodeId=8bfc1321218af, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Fri Sep 04 04:36:06 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400250, encodeId=a4c0140025052, content=<a href='/topic/show?id=10cc2901458' target=_blank style='color:#2F92EE;'>#免疫应答#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29014, encryptionId=10cc2901458, topicName=免疫应答)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a602256775, createdName=clmlylxy, createdTime=Fri Sep 04 04:36:06 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035398, encodeId=e2ca103539882, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Sep 02 16:36:06 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882186, encodeId=8209882186b5, content=<a href='/topic/show?id=8f4310385673' target=_blank style='color:#2F92EE;'>#COVID-19血清学抗体#</a> 抗体检测对二次感染风险的评估很重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103856, encryptionId=8f4310385673, topicName=COVID-19血清学抗体)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211106/ea1e44326e0946358e849b176cb8f385/463bdae7ebb241129b21a5680b639742.jpg, createdBy=329c5121051, createdName=liangying, createdTime=Wed Sep 02 13:52:06 CST 2020, time=2020-09-02, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1004072, encodeId=6ac510040e299, content=<a href='/topic/show?id=0e2531050aa' target=_blank style='color:#2F92EE;'>#冰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31050, encryptionId=0e2531050aa, topicName=冰岛)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=小小医者, createdTime=Fri Jul 30 22:13:56 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937952, encodeId=ba3d193e9523e, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun Apr 11 21:36:06 CST 2021, time=2021-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898539, encodeId=d9c21898539cb, content=<a href='/topic/show?id=0bdfe3394a4' target=_blank style='color:#2F92EE;'>#研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73394, encryptionId=0bdfe3394a4, topicName=研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Tue Feb 02 07:36:06 CST 2021, time=2021-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321218, encodeId=8bfc1321218af, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Fri Sep 04 04:36:06 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400250, encodeId=a4c0140025052, content=<a href='/topic/show?id=10cc2901458' target=_blank style='color:#2F92EE;'>#免疫应答#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29014, encryptionId=10cc2901458, topicName=免疫应答)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a602256775, createdName=clmlylxy, createdTime=Fri Sep 04 04:36:06 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035398, encodeId=e2ca103539882, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Sep 02 16:36:06 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882186, encodeId=8209882186b5, content=<a href='/topic/show?id=8f4310385673' target=_blank style='color:#2F92EE;'>#COVID-19血清学抗体#</a> 抗体检测对二次感染风险的评估很重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103856, encryptionId=8f4310385673, topicName=COVID-19血清学抗体)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211106/ea1e44326e0946358e849b176cb8f385/463bdae7ebb241129b21a5680b639742.jpg, createdBy=329c5121051, createdName=liangying, createdTime=Wed Sep 02 13:52:06 CST 2020, time=2020-09-02, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1004072, encodeId=6ac510040e299, content=<a href='/topic/show?id=0e2531050aa' target=_blank style='color:#2F92EE;'>#冰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31050, encryptionId=0e2531050aa, topicName=冰岛)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=小小医者, createdTime=Fri Jul 30 22:13:56 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937952, encodeId=ba3d193e9523e, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun Apr 11 21:36:06 CST 2021, time=2021-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898539, encodeId=d9c21898539cb, content=<a href='/topic/show?id=0bdfe3394a4' target=_blank style='color:#2F92EE;'>#研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73394, encryptionId=0bdfe3394a4, topicName=研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Tue Feb 02 07:36:06 CST 2021, time=2021-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321218, encodeId=8bfc1321218af, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Fri Sep 04 04:36:06 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400250, encodeId=a4c0140025052, content=<a href='/topic/show?id=10cc2901458' target=_blank style='color:#2F92EE;'>#免疫应答#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29014, encryptionId=10cc2901458, topicName=免疫应答)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a602256775, createdName=clmlylxy, createdTime=Fri Sep 04 04:36:06 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035398, encodeId=e2ca103539882, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Sep 02 16:36:06 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882186, encodeId=8209882186b5, content=<a href='/topic/show?id=8f4310385673' target=_blank style='color:#2F92EE;'>#COVID-19血清学抗体#</a> 抗体检测对二次感染风险的评估很重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103856, encryptionId=8f4310385673, topicName=COVID-19血清学抗体)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211106/ea1e44326e0946358e849b176cb8f385/463bdae7ebb241129b21a5680b639742.jpg, createdBy=329c5121051, createdName=liangying, createdTime=Wed Sep 02 13:52:06 CST 2020, time=2020-09-02, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1004072, encodeId=6ac510040e299, content=<a href='/topic/show?id=0e2531050aa' target=_blank style='color:#2F92EE;'>#冰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31050, encryptionId=0e2531050aa, topicName=冰岛)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=小小医者, createdTime=Fri Jul 30 22:13:56 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937952, encodeId=ba3d193e9523e, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun Apr 11 21:36:06 CST 2021, time=2021-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898539, encodeId=d9c21898539cb, content=<a href='/topic/show?id=0bdfe3394a4' target=_blank style='color:#2F92EE;'>#研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73394, encryptionId=0bdfe3394a4, topicName=研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Tue Feb 02 07:36:06 CST 2021, time=2021-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321218, encodeId=8bfc1321218af, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Fri Sep 04 04:36:06 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400250, encodeId=a4c0140025052, content=<a href='/topic/show?id=10cc2901458' target=_blank style='color:#2F92EE;'>#免疫应答#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29014, encryptionId=10cc2901458, topicName=免疫应答)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a602256775, createdName=clmlylxy, createdTime=Fri Sep 04 04:36:06 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035398, encodeId=e2ca103539882, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Sep 02 16:36:06 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882186, encodeId=8209882186b5, content=<a href='/topic/show?id=8f4310385673' target=_blank style='color:#2F92EE;'>#COVID-19血清学抗体#</a> 抗体检测对二次感染风险的评估很重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103856, encryptionId=8f4310385673, topicName=COVID-19血清学抗体)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211106/ea1e44326e0946358e849b176cb8f385/463bdae7ebb241129b21a5680b639742.jpg, createdBy=329c5121051, createdName=liangying, createdTime=Wed Sep 02 13:52:06 CST 2020, time=2020-09-02, status=1, ipAttribution=)]
    2020-09-02 旺医

    顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1004072, encodeId=6ac510040e299, content=<a href='/topic/show?id=0e2531050aa' target=_blank style='color:#2F92EE;'>#冰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31050, encryptionId=0e2531050aa, topicName=冰岛)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=小小医者, createdTime=Fri Jul 30 22:13:56 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937952, encodeId=ba3d193e9523e, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun Apr 11 21:36:06 CST 2021, time=2021-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898539, encodeId=d9c21898539cb, content=<a href='/topic/show?id=0bdfe3394a4' target=_blank style='color:#2F92EE;'>#研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73394, encryptionId=0bdfe3394a4, topicName=研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Tue Feb 02 07:36:06 CST 2021, time=2021-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321218, encodeId=8bfc1321218af, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Fri Sep 04 04:36:06 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400250, encodeId=a4c0140025052, content=<a href='/topic/show?id=10cc2901458' target=_blank style='color:#2F92EE;'>#免疫应答#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29014, encryptionId=10cc2901458, topicName=免疫应答)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a602256775, createdName=clmlylxy, createdTime=Fri Sep 04 04:36:06 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035398, encodeId=e2ca103539882, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Sep 02 16:36:06 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882186, encodeId=8209882186b5, content=<a href='/topic/show?id=8f4310385673' target=_blank style='color:#2F92EE;'>#COVID-19血清学抗体#</a> 抗体检测对二次感染风险的评估很重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103856, encryptionId=8f4310385673, topicName=COVID-19血清学抗体)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211106/ea1e44326e0946358e849b176cb8f385/463bdae7ebb241129b21a5680b639742.jpg, createdBy=329c5121051, createdName=liangying, createdTime=Wed Sep 02 13:52:06 CST 2020, time=2020-09-02, status=1, ipAttribution=)]
    2020-09-02 liangying

    #COVID-19血清学抗体# 抗体检测对二次感染风险的评估很重要

    0

Baidu
map
Baidu
map
Baidu
map